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Abstract
Although chemotherapy with procarbazine, lomustine and vincristine (PCV) is considered to be
well tolerated, side effects frequently lead to dose reduction or even discontinuation of treatment
of oligodendroglial brain tumors. The primary objective of the analysis was to retrospectively
compare progression-free survival (PFS) after PCV vs. PC chemotherapy (without vincristine to
avoid side effects). Patients were retrospectively identified from a database containing our patients
between 1990 and 2003. For the selected cases, all histopathology reports were re-evaluated by a
local neuropathologist. Based on the updated histology data, patients were included in the study if
they had at least one histological diagnosis of an oligodendroglial tumor. PFS after start of PCV (n
= 61) and PC (n = 84) chemotherapy identical (median 30 months). Multivariate analysis adjusting
for prognostic imbalances favouring the PC group showed a minor, statistically non-significant
benefit for PCV (hazard ratio 0.81, 95% confidence interval 0.53–1.25; p = 0.346). Younger age (<
50 y) was a statistically significant predictor of longer PFS. Significant advantages in terms of overall
survival after first diagnosis of oligodendroglial tumor (OS, n = 315) were found for patients < 50
y (p < 0.001), oligodendrogliomas versus oligoastrocytomas (p = 0.002), and WHO°II vs. °III (p <
0.001). Three risk groups regarding OS were identified. Findings support the hypothesis that PC
may be as effective as PCV chemotherapy, while avoiding the additonal risks of vincristine. Younger
age, lower tumor grade and histology of an oligodendroglioma were identified to be favorable
prognostic factors.
Background
Oligodendroglial brain tumors constitute a small sub-
group of tumors of the central nervous system. They
belong to the group of glial tumors. Histologically, so-
called pure oligodendrogliomas are usually composed of
a single cell type. Mixed gliomas, so-called oligoastrocyto-
mas, additionally contain astrocytes. The WHO classifica-
tion [1] distinguishes lowly malignant grade II tumors
and anaplastic grade III tumors. Malignant transforma-
tion in the course of disease is common for these tumors,
which is why affected patients have a reduced life expect-
ancy. Median survival of patients with astrocytic brain
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grade II tumors and about 2.8 years for WHO III tumors
[2-11]. Since PCV chemotherapy (procarbazine, CCNU,
vincristine) became available as a new therapeutic option
in addition to radiotherapy and surgical resection, neuro-
oncologists have shown an increasing interest in oli-
godendroglial tumors in recent years.
Published studies on oligodendrogliomas are very hetero-
geneous in terms of patient numbers, treatment modali-
ties and histological features and therefore difficult to
compare. Many investigators have confirmed the prog-
nostic value of 1p/19q loss and have shown that this
change occurs very early in the course of tumor develop-
ment [12-16]. The efficacy of available therapies is still
limited despite new insights into the molecular structure
of oligodendrogliomas. Temozolomide is typically the
first-line drug for oral chemotherapy because it is assumed
to have fewer side effects than the PCV regimen. The first
clinical study directly comparing temozolomide and PCV
treatment in patients with malignant oligodendroglial
tumors is currently underway [17-19]. However, the
standard combination of procarbazine, CCNU and vinc-
ristine is associated with a high number of severe side
effects. The main side effects of vincristine are peripheral
neuropathy and constipation. Vincristine binds to tubulin
dimers causing disassembly of microtubules. Disruption
of the microtubules arrests mitosis in metaphase. The
vinca alkaloids therefore affect all rapidly dividing cells,
including cancer cells but also the intestinal epithelium
and bone marrow. Based on the clinical impression that
vincristine was responsible for many side effects and had
no additional benefit for the patients, treatment in
Freiburg was changed to therapy without vincristine (PC
chemotherapy).
The primary objective of this study was to retrospectively
compare progression-free survival (PFS) after PCV chem-
otherapy versus PC chemotherapy according to the
Freiburg regimen, which was introduced in 1996. Adjust-
ments were made for age, previous resection, histological
type and grade, and Karnofsky performance score (KPS).
PFS after resection was evaluated descriptively. In addi-
tion, overall survival from first diagnosis of oligodendro-




Patients were retrospectively identified from the MS
ACCESS database of our department containing all
patients treated since Jan. 1, 1990. The cut-off for inclu-
sion in the study was Dec. 31, 2003. Patients were selected
for review if they had at least one diagnosis of oligoden-
droglioma or oligoastrocytoma. Patients gave their
informed consent for data acquisition. The study was
approved by the local ethical committee. For the selected
cases, all histopathology reports and specimens removed
at our department were re-evaluated by a local neu-
ropathologist according to current standards. Based on
the updated histology reports, patients were included in
the study if they had at least one histological diagnosis of
an oligodendroglial tumor, i.e. WHO grade II or III oli-
godendroglioma or WHO grade II or III oligoastrocytoma,
and if follow-up data were available. Of 369 patients who
fulfilled the initial criteria, 54 were excluded either
because histological re-evaluation failed to confirm oli-
godendroglial tumor or because no follow-up was availa-
ble, leaving 315 patients for inclusion in the analysis.
Staging and grading
Patients underwent stereotactic serial biopsies as previ-
ously described [20]. Intraoperatively, specimens were
obtained for smear preparation and/or paraffin conserva-
tion. A mixed oligodendroglioma was diagnosed when
the tumor contained at least 25% of oligodendrocytic ele-
ments. For the purpose of this study, grading and staging
of the tumors were postoperatively re-evaluated by a
board-certified neuropathologist [20]. If a follow-up
biopsy rated a tumor as more benign than previous biop-
sies, the more recent benign diagnosis was retrospectively
assumed for the earlier biopsies as well. This occurred in 5
patients and 5 biopsies.
Treatments
Patients with anaplastic oligoastrocytomas or oligoden-
drogliomas (WHO grade III) usually underwent radio-
therapy with a maximum dose of 60 Gy in 30 daily
fractions within the first 6 weeks after surgery. The
planned target volume was variable and was defined on
the basis of postoperative magnetic resonance imaging
(MRI) or computed tomography (CT) findings.
PCV chemotherapy consisted in standard cycles of 110
mg/m2 of oral lomustine on day one (maximum of 200
mg) together with ondansetron (domperidone or meto-
copramide) as an antiemetic drug, followed by 60 mg/m2
of oral procarbazine on days 8 through 21, and 1.4 mg/m2
of IV vincristine on days 8 and 29 (maximum of 2 mg/
day). Cycles were repeated every 6 weeks. PC chemother-
apy was used in single cases starting in 1996 and has been
in routine use since 2000. The dosages of lomustine and
procarbazine were the same, the cycles were extended to
12 weeks.
PCV and PC chemotherapy were continued for at least 3
cycles. Tumor response was evaluated by means of con-
trast-enhanced imaging (CT or MRI) every three months
and therapy discontinued if there was tumor regression or
stable disease according to MacDonald criteria for at least
6 months [21]. In addition chemotherapy was readjustedPage 2 of 9
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toxicity.
Seed implantation was used instead of fractionated radio-
therapy to treat tumors with a maximum diameter of 30
mm and a spherical configuration. I125 seeds in a 5-mm
titanium capsule were temporarily implanted for 20–30
days to reach the 60 Gy isodose at the tumor margin.
Microsurgical resection was typically performed on
tumors not involving the basal ganglia or eloquent
regions of the brain, and only exceptionally for recurrent
tumors not responding to chemotherapy and radiation
therapy.
Follow-up and evaluation criteria
After the end of treatment, follow-up examinations
including contrast-enhanced MRI or CT were performed
at 6-month intervals. For patients not followed up at our
hospital, follow-up dates, times of progression, therapies
in other hospitals and survival data were sought using
both a questionnaire, which was sent to the patients, and
telephone calls to the caretakers. Information on the last
follow-up of surviving patients was obtained in the period
between June 2004 and December 2005.
Progression-free survival was the primary endpoint,
defined as the interval from initiation of treatment (PCV,
PC, resection or seed implantation) to the next progres-
sion or death. Based on the available data, progression
was retrospectively determined as either image-defined
progression (>25% contrast-enhanced tumor) or initia-
tion of subsequent treatment (chemotherapy, radiation,
resection or seed implantation ≥ 4 weeks after start of
treatment; treatments within 4 weeks were interpreted as
planned interventions). For comparison of PCV (n = 61)
versus PC (n = 84), patients were retrospectively assigned
to the treatment groups based on the regimen they
received first, excluding 167 patients who received neither
PCV nor PC after diagnosis of oligodendroglioma or oli-
goastrocytoma, and 3 patients whose follow-up ended
with the administration of chemotherapy. PFS of patients
with resection (n = 98) was evaluated descriptively. Over-
all survival (OS) was defined as time from first diagnosis
of oligodendroglioma or oligoastrocytoma to death from
any cause and was assessed in the entire group of patients.
Statistical methods
PFS and OS were estimated by the Kaplan-Meier method,
censoring observations at the time of last follow-up if the
respective event was not observed [22]. Median follow-up
was determined using the reverse Kaplan-Meier estimator
[23]. Prognostic factors (age </≥50 years) [24], previous
resection, histological type and grade, Karnofsky perform-
ance status (</≥90) [25], and a treatment indicator (where
applicable) were all fitted together in pre-specified Cox
regression models. In addition, the treatment indicator in
the PCV versus PC comparison was subjected to explora-
tory sensitivity analyses to study the potential effect of cor-
relation between treatment and other factors. For the OS
model a prognostic score was calculated for each patient.
Kaplan-Meier plots were produced for three risk groups of
equal size with low, medium and high risk. Toxicity rates
were compared by Fisher's exact test. Two-sided 95% con-
fidence intervals were used and statistical significance
defined as p < 0.05 based on two-sided tests.
Results
After re-evaluation of histological findings, 315 patients
with oligodendroglial tumors and follow-up data were
available for analysis. The majority of patients were
younger than 50 when they were first diagnosed with an
oligodendroglial tumor. Sixty-four percent of the patients
(n = 202) were men. At the time of diagnosis, 26% of
patients (n = 83) had already undergone tumor resection.
The histological diagnoses were grade II oligodendrogli-
oma in 28% (n = 87), grade III oligodendroglioma in 3%
(n = 10), grade II oligoastrocytoma in 57% (n = 181), and
grade III oligoastrocytoma in 12% (n = 37). In two
patients with oligoastrocytoma definitive grading was not
possible (Table 1).
In the total study population of 315 patients, 145 patients
with a diagnosis of oligodendroglial tumor were treated
by PCV (n = 61) or PC (n = 84) chemotherapy. In three
additional cases, follow-up ended with the completion of
Table 1: Description of patient population at the time of first 
diagnosis of oligodendroglioma or oligoastrocytoma (n = 315)
n %
Age (in years) <20 15 5%
≥20 – <30 53 17%
≥30 – <40 87 28%
≥40 – <50 82 26%
≥50 – <60 43 14%
≥60 – <70 26 8%
≥70 9 3%
median (range) 40 (4 – 77)
Sex male 202 64%
female 113 36%
Previous resection yes 83 26%
no 232 74%
Histology and grade Oligodendroglioma, WHO II 87 28%
Oligodendroglioma, WHO III 10 3%
Oligoastrocytoma, WHO II 181 57%
Oligoastrocytoma, WHO III 37 12%Page 3 of 9
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to 2001; PC chemotherapy was used only in individual
patients before 2000 and then routinely until the end of
the observation period in 2005. 9 patients underwent PC
chemotherapy after PCV was discontinued due to toxicity.
They were included in the PCV group. Age and sex distri-
bution were comparable in both treatment groups (Table
2). Oligodendroglioma was present in about a quarter of
both PCV and PC patients, respectively. Median time from
diagnosis of oligodendroglioma to onset of chemother-
apy was 2.8 (PVC) versus 0.4 years. Histological grading
and Karnofsky performance status (KPS) at initiation of
chemotherapy were better in PC patients, with WHO
grade II in 52% (PCV, n = 32) versus 67% (PC, n = 56),
and KPS 90 or 100 in 59% (PCV, n = 35) versus 66% (PC,
n = 55). 19% (n = 31) of PCV and 23% (n = 19) of PC
patients had received radiotherapy or a seed implantation
before PC(V). Tumor resection had been performed
before chemotherapy in 49% (n = 30) of patients in the
PCV group versus 27% (n = 23) in the PC group. Surgical
Table 2: Description of patient population at time of PCV or PC treatment
PCV n = 61 PC n = 84
Age (in years) < 50 40 (66%) 53 (63%)
≥50 21 (34%) 31 (37%)
median (range) 44 (14 – 73) 42 (19 – 77)
Sex male 38 (62%) 54 (64%)
female 23 (38%) 30 (36%)
Time from diagnosis of oligodendroglioma to onset of chemotherapy (in years) median (range) 2.8 (0 – 17) 0.4 (0 – 18)
Resection prior to chemo-therapy yes 30 (49%) 23 (27%)
no 31 (51%) 61 (73%)
Radiotherapy or seed implantation prior to chemotherapy yes 30 (49%) 54 (64%)
no 31 (51%) 65 (36%)
Histology and grade Oligodendroglioma, WHO II 10 (16%) 16 (19%)
Oligodendroglioma, WHO III 6 (10%) 7 (8%)
Oligoastrocytoma, WHO II 22 (36%) 40 (48%)
Oligoastrocytoma, WHO III 21 (34%) 18 (21%)
Other, WHO III/IV° 2 (3%) 3 (4%)
Karnofsky performance score < 90 24 (41%) 28 (34%)
≥90 35 (59%) 55 (66%)
Unknown 2 1
Table 3: Determinants of progression-free survival after PCV (n = 59) and PC (n = 83) treatment in patients with complete data (100 
events)
Hazard ratio* 95% confidence interval p value
Treatment PCV vs. PC 0.81 0.53–1.25 0.346
Age (in years) < 50 vs. ≥50 0.64 0.41–1.00 0.051
Resection before chemotherapy yes vs. no 1.61 1.01–2.58 0.047
Histology Oligoastrocytoma vs oligodendroglioma 1.34 0.83–2.18 0.487
Other vs oligodendroglioma 1.42 0.46–4.39
WHO grade II vs III/IV 0.75 0.49–1.14 0.176
Karnofsky performance score < 90 vs ≥90 1.26 0.81–1.96 0.304
* A hazard ratio < 1 (> 1) indicates an effect in favor of the first (the second) group in terms of progression-free survival.Page 4 of 9
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tumors and significant mass effect prior to surgery but its
effect is controversial [26]. Therefore it is not clear a priori
which group is favored by the imbalance with respect to
resection.
Regarding outcome, 102 events (85 progressions, 17
deaths) were observed with respect to PFS after a median
follow-up time of 6 years. The crude PFS rates of PCV and
PC patients were nearly identical over the first four years
following start of treatment (Figure 1). Median PFS was 2
years 6 months after both PCV and PC (95% confidence
interval [95%-CI]: 1 year 8 months – 3 years 1 month).
The adjusted hazard ratio, which corrects for the above-
mentioned imbalances, was 0.81 for PCV versus PC (95%-
CI: 0.53–1.25; p = 0.35), favoring PCV. Young age, no pre-
vious resection, oligodendroglioma, WHO grade II and
KPS ≥ 90 were factors associated with good prognosis,
with previous resection reaching statistical significance (p
= 0.047) and age borderline significance (p = 0.051; Table
Progression-free survival for PCV (n = 61) vs PC (n = 84)Figu  1
Progression-free survival for PCV (n = 61) vs PC (n = 84).
Progression-free survival after resection (n = 98)Figu  2
Progression-free survival after resection (n = 98).Page 5 of 9
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ity of the estimated hazard ratio for PCV versus PC, sensi-
tivity analyses studying effects in subgroups defined by
WHO grade, KPS and resection were performed. The
resulting PCV versus PC hazard ratios within subgroups
(adjusted for the other factors) ranged between 0.62 for
WHO grade III tumors and 1.04 for patients without pre-
vious resection, but none was statistically significant (data
not shown).
PFS after chemotherapy was significantly shorter in
patients with prior resection (hazard ratio 1.61, 95%-CI:
1.01–2.58, p = 0.047; Table 3). Figure 2 shows the PFS
rates after resection in 98 patients. Median time to pro-
gression or death was 2 years (95%-CI: 1 year 2 months –
3 years 2 months; 81 progressions, 10 deaths).
Evaluation of toxicity revealed a predominance of neuro-
logical symptoms in the PCV group. There was no differ-
ence in the occurrence of Grade 2, 3 and 4 side effects
in further parameters except white blood cell count
(Table 5).
In the entire population of 315 patients, 120 deaths
occurred during a median follow-up period of 7 years for
OS after first diagnosis of oligodendroglial tumor. 88%,
77%, 67%, 63% and 52% of patients survived for more
than 2, 4, 6, 8, and 10 years, respectively. Young age, oli-
godendroglioma and WHO grade II showed large and sta-
tistically significant favorable effects on OS, while no
relevant influence could be demonstrated for resection
(Table 4). Three groups of patients were identified as low,
medium and high risk groups. Patients aged under 50
with oligoastrocytoma of WHO grade II and no resection
constituted the largest group (n = 122) with medium risk.
Those either aged ≥ 50 or aged under 50 with WHO grade
III tumors were at high risk (n = 105). Patients were at low
risk if they were aged under 50, had a WHO grade II tumor
and either a previous resection or oligoastrocytoma but
no previous resection (n = 88, Figure 3).
Table 5: NCI Common Toxicity Criteria for PCV and PC treated patients (n = 84 vs. n = 61 respectively)
Category Regime Toxicity Grade 2 Grade 3 Grade 4 p-value
Neurological PC Sensory 0 0% 0 0% 0 0% 0.002
PCV 10 12% 3 (4%) 0 (0%)
PC Motor 0 (0%) 0 (0%) 0 (0%) 0.26
PCV 3 (4%) 0 (0%) 0 (0%)
Gastrointestinal PC Nausea 15 (25%) 3 (5%) 0 (0%) 0.65
PCV 15 (18%) 5 (6%) 0 (0%)
PC Vomiting 10 (16%) 4 (7%) 0 (0%) 0.62
PCV 9 (11%) 5 (6%) 0 (0%)
Blood/Bone Marrow PC WBC 35 (57%) 15 (25%) 1 (2%)  < 0.001
PCV 25 (30%) 14 (17%) 2 (2%)
PC PLT 10 (16%) 8 (13%) 2 (3%) 0.20
PCV 8 (10%) 6 (7%) 1 (1%)
PC Hgb 7 (11%) 5 (8%) 1 (2%) 0.24
PCV 6 (7%) 3 (4%) 0 (0%)
Allergy PC Allergy 6 (10%) 0 (0%) 0 (0%) 0.33
PCV 4 (5%) 2 (2%) 0 (0%)Page 6 of 9
(page number not for citation purposes)
BMC Neurology 2009, 9:33 http://www.biomedcentral.com/1471-2377/9/33Discussion
The significance of the oligodendroglial tumor compo-
nent in the histopathological diagnosis has been increas-
ingly recognized with the advent of new
chemotherapeutical options over the last decade. In gen-
eral, patients with oligodendroglial tumors have better
therapeutic options and a better prognosis compared to
patients with purely astrocytic tumors. However, it is
assumed that the more favorable prognosis of these
patients is crucially determined by the treatment per-
formed. To investigate the effects of different therapies on
prognosis, we undertook this retrospective analysis of 315
consecutive patients diagnosed with an oligodendroglial
tumor at our department from 1990 to 2003. Our study
population is comparable to the patient populations
investigated in other large studies in terms of age distribu-
tion and frequency of histological diagnoses [27,28].
Another aim of the retrospective analysis was to find out
whether combined chemotherapy with procarbazine and
CCNU without vincristine may be equally effective even
when the cycle of administration is prolonged. The crude
progression-free survival rates found in our patients after
initiation of PCV and PC therapy are indeed very similar,
while more detailed analyses adjusting for some prognos-
tic imbalances which favored the PC group show a minor
and statistically non-significant treatment benefit for PCV.
Obviously, these results need to be interpreted with care.
In addition to the absence of randomization, the time-lag
of nearly a decade between PCV and PC treatment of our
patients introduces a great potential to bias treatment
comparisons. During this period a lot more than chemo-
therapy treatment has been changed. However, the study
does add some evidence to the hypothesis that vincristine
administration may be unnecessary. Another advantage of
the PC regimen is that it allows completely oral adminis-
Overall survival after first diagnosis of oligodendroglioma or oligoastrocytoma (n = 315) by risk group (low, medium, high risk)Figure 3
Overall survival after first diagnosis of oligodendroglioma or oligoastrocytoma (n = 315) by risk group (low, 
medium, high risk).
Table 4: Determinants of overall survival after first diagnosis of oligodendroglioma or oligoastrocytoma (n = 315 patients, 120 deaths)
Hazard ratio* 95% confidence interval p-value
Age (in years) < 50 vs ≥50 0.40 0.27–0.59 < 0.001
Previous resection yes vs no 0.87 0.57–1.32 0.506
Histology Oligoastrocytoma vs Oligodendroglioma 1.99 1.28–3.10 0.002
WHO grade II vs III 0.39 0.24–0.61 < 0.001
* A hazard ratio < 1 (> 1) indicates an effect in favor of the first (the second) group in terms of overall survival.Page 7 of 9
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tient basis.
PFS after PCV versus PC was determined from the start of
chemotherapy, independent of previous treatments.
Tumor progression was assumed if a new therapy was ini-
tiated later than four weeks after preceding treatment
assuming retrospectively that this was done for recurrent
tumor while a second therapy within the first four weeks
was interpreted as a planned intervention. However, since
we analyzed the data retrospectively, standardized and
reliable radiological follow-up data are not available in all
cases. Therefore, our results need to be validated further in
prospective studies. The median interval until progression
after tumor resection was only two years (Figure 2). Over-
all survival of patients who already underwent resection
before the first diagnosis of an oligodendroglial tumor did
not differ from that of the remaining patients (Table 4).
Taking in account latest published data on the prognostic
importance of total resection, we have to consider a strong
bias within the resection group. The extent of resection
was not evaluated. Patients underwent surgery mostly in
cases with severe mass effects. Therefore results (Table 3
and Figure 2) must not allow one to conclude anything
about the value of resection but rather suggest that the
overall prognosis of these tumors is influenced by numer-
ous additional factors. Furthermore, genetic factors, such
as 1p19q constellations have been identified as favorable
prognostic factors for temozolomide treatment of oli-
godendroglial tumors [29]. More evaluations are required
to elucidate this question.
A lower tumor grade (WHO grade II) and younger age
were significantly associated with a favorable prognosis
regarding OS after first diagnosis of oligodendroglial
tumor. This observation is in agreement with earlier
reports [30,31].
The disadvantages of Vincristine might be avoidable. PCV
leads to significantly more neurological symptoms than
PC alone (Table 5). This corresponds to the data for PCV
administration of other authors [32].
Conclusion
In summary, our retrospective results show the benefits of
combined therapeutic approaches in patients with oli-
godendroglial tumors. When carefully considering an
individual patient's situation, combined chemotherapy
with PC appears to be just as effective as conventional
PCV therapy. In recent years, temozolomide has been
increasingly used because of its lower rate of side effects.
However, results of a direct comparison of temozolimide
with established chemotherapeutic regimens are still lack-
ing.
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